Uremic exocrine pancreopathy
Most patients dying of uremia develop significant pancreatic histologic abnormalities. The etiology and clinical relevance of these changes and whether they constitute a specific uremic exocrine pancreopathy are still speculative. Much of the recent literature has focused on the quantitative evaluation of pancreatic exocrine function in chronic renal failure (CRF), but differing investigative techniques and limited sample size have hindered the attempts to identify discrete exocrine pancreatic failure in uremia. This problem is of more than academic interest because it impacts on the quality of life of the uremic patient.
Histopathology
Baggenstoss (1) in 1948 described 270 patients who died of uremia with no known pancreatic disease and 200 age matched nonuremic controls. The uremic pancreas frequently revealed dilatation of the acini and accompanying tiny ductules, flattening of the epithelial cell lining, and inspissation of acinar secretion. These changes were diffusely present and of a moderate to severe degree in 44% of uremics compared with mild to moderate changes in 20% of controls. Avram (2) confirmed these findings in 21 consecutive autopsies of maintenance hemodialysis patients with no past history of pancreatitis or x-ray evidence of pancreatic disease. Again the changes were diffuse and consisted of duct ectasis with inspissated material, periductal fibrosis, ductular proliferation, acinar ductal metaplasia, and interstitial inflammation and fibrosis.
In uremic macaques, whose pancreatic histology under light microscopy resembles that of uremic humans, Bronson et al (3) used electron microscopy, histochemistry and 3-D reconstruction to show that most cells lining ectatic acini were atrophic acinar cells. They found surprisingly little evidence to support the ductular proliferation seen under light microscopy. Apparently, uremia is associated with a pancreopathy in which the primary derangement is acinar ectasia with inspissated pancreatic secretions. Inflammation and fibrosis are secondary changes in long standing disease.
Etiology
In the predialysis era, pancreatic inspissation was thought to be the primary event occurring as a consequence of dehydration (1) . In hemodialysis patients, repeated volume depletion has been invoked (2, 4) . While volume changes may be important, it is likely that additional factors are involved in producing this histologic picture. Such factors may include alterations in pancreotrophic hormones, secondary hyperparathyroidism, hypertriglyceridemia, the uremic syndrome per se, or atypical bouts of pancreatitis. Of the pancreotrophic hormones, cholecystokinin (CCK) (5) and secretin (6) are degraded and excreted through renal mechanisms and hence their levels are elevated in patients with CRF (7). The level of pancreatic polypeptide, a hormone known to inhibit pancreatic bicarbonate secretion, directly correlates with the degree of renal failure (8) and may be increased ten fold in uremic subjects (9) . These hormones regulate pancreatic exocrine function and alterations in their blood levels can be pathophysiologically significant. Avram et al (4) reports that uremic patients with pancreatic histopathology have higher levels of serum parathyroid hormone (PTH) than uremics with normal pancreatic histology. Hyperparathyroidism may influence exocrine function by changing pancreatic cell calcium. Excess ionic calcium within the pancreas activates trypsin (4) and increased acinar cell calcium uptake causes trypsinogen release within the pancreas (10). These observations may have a bearing on the pathologic changes. Stepan et al (11) found in CRF patients higher serum pancreatic amylase levels in subjects with higher serum PTH levels than their uremic counterparts with lower PTH values. Although this observation is consistent with the postulate that hyperparathyroidism is etiologically important, the depen1:lence of both PTH levels and amylase clearance on the level of renal function limits the relevance of this finding.
Equally difficult to prove are the suggestions that the observed histopathology may result from a silent subclinical pancreatitis or repeated episodes of atypical acute pancreatitis. Among Avram's (2, 4) 21 CRF patients 86% had nonspecific epigastric pain, nausea, or vomiting at sometime during their course but none had a typical episode of acute pancreatitis. These symptoms, moreover, are common in the dialysis population and have multiple etiologies. There is no evidence to support an increased incidence of acute pancreatitis in CRF. In a large series of stable dialysis patients 7 of 259 patients were diagnosed with acute pancreatitis, 5 were attributed to malignant hypertension and 2 had a history of alcoholism (12) .
Exocrine Function
Exocrine function has been evaluated using duodenal aspirate analysis of pancreatic juice after various stimulatory techniques. Results of available studies are summarized in Table 1 . Bartos et al (13) studied 16 CRF patients and an equal number with mild renal insufficiency. The parameters evaluated included volume, peak bicarbonate concentration and total bicarbonate excretion, and amylase and lipase output. Seventy-five percent of the patients had exocrine hypofunction, 50% of them having at least 2 of the measured parameters significantly lowered. A decreased peak bicarbonate concentration, which correlated with the measured serum bicarbonate, was the most striking abnormality. Interestingly, the least frequent abnormality was a lowered volume output, which may speak in part against inspissation. Dinoso et al (14) found that basal bicarbonate output in 10 CRF patients on hemodialysis (measured predialysis) and 15 CRF patients with a previous renal transplantation were only one-third that of a hospitalized control group. After intravenous secretin stimulation, however, no significant difference in bicarbonate output were found, furthermore, basal levels measured postdialysis were more than double pre-dialysis levels. These results speak against a significant pancreatic defect in bicarbonate secretion and implicate systemic acidemia as a pathogenetic factor.
Bartos et al (13) found a decreased amylase output in response to pancreozymen stimulation in 31% and decreased lipase output in 44% of uremic subjects. Sachs et al (15) confirmed that secretin-pancreozymen stimulation resulted in a significantly lowered amylase and lipase output in 8 patients on hemodialysis. In contrast; Owyang et al (16) found increased trypsin output but no difference in lipase output after both intravenous CCK and duodenal mannitol perfusion in 8 patients on maintenance hemodialysis. These apparent discrepancies are likely to be due to population sampling. It is highly probable that exocrine hypofunction is not a universal finding and may be present to variable degrees. Many studies have measured serum levels of trypsin or its trypsinogen precursors (10). Geokas et al (17) found elevated plasma concentration of anionic trypsinogen in 26 patients on hemodialysis. They also report that bilateral nephrectomy in dogs elevated the basal plasma levels of both anionic and cationic trypsinogen with a much greater and prolonged increase after CCK stimulation. As these zymogens are cleared by the kidney, it is difficult to implicate pancreatic pathophysiology as a cause for their changing levels.
In summary, pancreatic bicarbonate secretion is decreased in CRF and the degree of impairment is influenced in part by systemic acidemia. Evidence also suggests impaired pancreatic amylase secretion and decreased lipase output, though this is less clear cut. Plasma levels of trypsin and trypsinogen precursors are consistently elevated in CRF but studies on the pancreatic secretion of these enzymes are conflicting. The clinical significance of these functional abnormalities is illustrated by the work of sachs and his colleagues (15, 18) . Four of eight hemodialysis patients they studied had steatorrhea and wasting that responded to pancreatic enzyme supplementation. Confirmation of these findings in a larger patient population is of obvious clinical relevance.
Experimental studies
Evaluation of uremic pancreopathy in experimental models of uremia is limited. Recently Kaysen et al (19) examined pancreatic composition and protein secretion kinetics of isolated dispersed pancreatic acini from 7/8 nephrectomy rats and sham controls. Uremic rats had increases in pancreatic weight, RNA/DNA and protein/DNA ratios, and total DNA content, suggesting that CRF induces pancreatic hypertrophy and hyperplasia. Increased immunoreactive cationic trypsinogen and total trypsin-like activity were found in the pancreas of the CRF rats but no difference in circulating serum levels suggesting a decreased pancreatic protein secretion. Further, CCK induced release of trypsinogen and chymotrypsinogen from acini of uremic rats was considerably lower than that of sham rats. These findings stand in contrast to the elevated serum levels detected in humans. The incorporation of 3H-leucine into proteins and the release of proteins into the medium was less with the acini of uremic rats than in those of sham rats both in the presence and absence of CCK. The decreased incorporation and release were not the result of reduced uptake of the precursor amino acids. Interestingly, these investigators also found a decreased protease inhibitory activity in the renal failure pancreas which may implicate autodigestion in this animal model of uremic pancreopathy.
Future research
Though the histopathologic changes in the pancreas of patients with CRF are indisputable it is difficult, from available data, to establish an etiology or a clear picture of pancreatic exocrine hypofunction. Future investigation should therefore focus on a better understanding of pancreatic exocrine performance in uremia and evaluation of the role, if any, of enzyme supplementation.
